最近胶质母细胞瘤的多模态治疗进展。
Recent advancements in multimodality treatment of gliomas.
机构信息
Department of Radiation Oncology, Arthur G James Comprehensive Cancer Center & Richard L Solove Research Institute, The Ohio State University Medical Center, Columbus, 43210, USA.
出版信息
Future Oncol. 2011 Oct;7(10):1169-83. doi: 10.2217/fon.11.102.
Abstract
Gliomas account for the vast majority of malignant adult brain tumors. Even though tremendous effort has been made to optimize treatment of patients with high-grade glioma, the prognosis remains poor, especially for patients with glioblastoma. The dismal prognosis conferred by these tumors is in part caused by the tendency to diffusely infiltrate into neighboring brain tissue, but also by the inherent resistance of these tumors to both chemotherapy and radiation. This article reviews the recent advancements in multimodality treatment of patients with gliomas, both in the primary and recurrent setting, with an emphasis on the emerging targeted therapies. Moreover, the external beam radiotherapy options, including intensity modulated radiotherapy and particle (proton and carbon ion) radiotherapy are reviewed.
摘要
神经胶质瘤占成人脑肿瘤的绝大多数。尽管为优化高级别神经胶质瘤患者的治疗做出了巨大努力，但预后仍然不佳，尤其是胶质母细胞瘤患者。这些肿瘤带来的不良预后部分是由于它们向邻近脑组织弥漫性浸润的倾向，也部分是由于这些肿瘤对化疗和放疗的固有耐药性。本文综述了在原发性和复发性脑胶质瘤患者的多模态治疗方面的最新进展，重点介绍了新兴的靶向治疗。此外，还回顾了外照射放疗的选择，包括调强放疗和粒子（质子和碳离子）放疗。
相似文献
1
Recent advancements in multimodality treatment of gliomas.
Future Oncol. 2011 Oct;7(10):1169-83. doi: 10.2217/fon.11.102.
2
Understanding high grade glioma: molecular mechanism, therapy and comprehensive management.
Cancer Lett. 2013 May 1;331(2):139-46. doi: 10.1016/j.canlet.2012.12.024. Epub 2013 Jan 20.
3
[Treatment modalities for malignant gliomas with reference to their pathophysiology].
Gan To Kagaku Ryoho. 1986 Jan;13(1):11-7.
4
Management of diffuse glioma.
Presse Med. 2018 Nov-Dec;47(11-12 Pt 2):e199-e212. doi: 10.1016/j.lpm.2018.04.014. Epub 2018 Oct 29.
5
[Controversy on treatments for gliomas].
Gan To Kagaku Ryoho. 1998 Sep;25(11):1650-6.
6
[Management of gliomas].
Cancer Radiother. 2014 Oct;18(5-6):461-7. doi: 10.1016/j.canrad.2014.07.147. Epub 2014 Sep 4.
7
Congress of Neurological Surgeons systematic review and evidence‑based guidelines on the management of recurrent diffuse low-grade glioma: update.
J Neurooncol. 2025 Jan;171(1):105-130. doi: 10.1007/s11060-024-04838-5. Epub 2024 Oct 14.
8
Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas.
PLoS One. 2020 Dec 29;15(12):e0244383. doi: 10.1371/journal.pone.0244383. eCollection 2020.
9
Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy.
J Neurooncol. 1996 May-Jun;28(2-3):207-22. doi: 10.1007/BF00250200.
10
Multimodality treatment of malignant gliomas. Comparison of several adjuvant approaches.
Zentralbl Neurochir. 1981;42(2-3):99-119.
引用本文的文献
1
Identification and Validation of Prognostic Genes Related to Histone Lactylation Modification in Glioblastoma: An Integrated Analysis of Transcriptome and Single-cell RNA Sequencing.
J Cancer. 2025 Mar 21;16(7):2145-2166. doi: 10.7150/jca.110646. eCollection 2025.
2
The pathogenesis mechanism and potential clinical value of lncRNA in gliomas.
Discov Oncol. 2024 Jul 5;15(1):266. doi: 10.1007/s12672-024-01144-4.
3
CDCA3 is a potential biomarker for glioma malignancy and targeted therapy.
Medicine (Baltimore). 2024 May 10;103(19):e38066. doi: 10.1097/MD.0000000000038066.
4
Establishment of a 3D Model to Characterize the Radioresponse of Patient-Derived Glioblastoma Cells.
Cancers (Basel). 2023 Aug 10;15(16):4051. doi: 10.3390/cancers15164051.
5
High EZH2 Protein Expression Is a Poor Prognostic Predictor in IDH1 R132H-Negative Gliomas.
Diagnostics (Basel). 2022 Sep 30;12(10):2383. doi: 10.3390/diagnostics12102383.
6
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.
Oncologist. 2023 Jan 18;28(1):e45-e53. doi: 10.1093/oncolo/oyac202.
7
Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma.
Int J Mol Sci. 2021 Sep 7;22(18):9673. doi: 10.3390/ijms22189673.
8
Cannabidiol Induces Apoptosis and Perturbs Mitochondrial Function in Human and Canine Glioma Cells.
Front Pharmacol. 2021 Aug 11;12:725136. doi: 10.3389/fphar.2021.725136. eCollection 2021.
9
Immunohistochemical expression of MGMT in gliomas and its role in ascertaining patient survival.
Med Pharm Rep. 2021 Jul;94(3):318-324. doi: 10.15386/mpr-1951. Epub 2021 Jul 29.
10
Ischemic Stroke After Tumor Resection in a Patient With Glioblastoma Multiforme.
Cureus. 2021 Feb 8;13(2):e13232. doi: 10.7759/cureus.13232.
本文引用的文献
1
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.
Invest New Drugs. 2015 Feb;33(1):247-53. doi: 10.1007/s10637-014-0186-2. Epub 2014 Nov 13.
2
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2018-24. doi: 10.1016/j.ijrobp.2010.12.074. Epub 2011 Apr 12.
3
Imaging of tumor physiology: impacts on clinical radiation oncology.
Exp Oncol. 2010 Sep;32(3):149-52.
4
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
J Clin Oncol. 2011 Jan 10;29(2):142-8. doi: 10.1200/JCO.2010.30.2729. Epub 2010 Dec 6.
5
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
J Clin Oncol. 2010 Nov 1;28(31):4722-9. doi: 10.1200/JCO.2010.28.6963. Epub 2010 Oct 4.
6
Molecular diagnostics of gliomas: the clinical perspective.
Acta Neuropathol. 2010 Nov;120(5):585-92. doi: 10.1007/s00401-010-0750-6. Epub 2010 Sep 23.
7
Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
BMC Cancer. 2010 Sep 6;10:478. doi: 10.1186/1471-2407-10-478.
8
PET for radiation treatment planning of brain tumours.
Radiother Oncol. 2010 Sep;96(3):325-7. doi: 10.1016/j.radonc.2010.08.001. Epub 2010 Aug 20.
9
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Cancer. 2010 Aug 1;116(15):3663-9. doi: 10.1002/cncr.25275.
10
Carbon ion radiotherapy: clinical experiences at National Institute of Radiological Science (NIRS).
J Radiat Res. 2010;51(4):355-64. doi: 10.1269/jrr.10016. Epub 2010 May 28.
Zotero 插件